Xenetic Biosciences Announces Oral Presentation at ASH Meeting
Xenetic Biosciences announced an oral presentation at the 68th ASH Annual Meeting highlighting DNase I as a potential strategy to overcome CAR T-cell resistance.
Related stories
Kvika Banki Reports Q3 2026 Financial Results
Kvika banki hf. reported return on tangible equity of 18.9% for the quarter.
M impact | EQUITY | Nov 04, 2026, 03:35 PM UTC
NYSE American single-stock trading halt, symbol not given — additional information requested (last $6.97)
NYSE American halted trading in a single listed security (additional information requested). Last price $6.97.
L impact | EQUITY | Nov 04, 2026, 03:35 PM UTC
Ronesans Gayrimenkul Q3 Revenue Rises to 4.8 Billion Lira
Q3 revenue was 4.8 billion lira, compared with 4.0 billion lira a year earlier.
M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC
Ronesans Gayrimenkul Yatirim Reports Q3 Net Profit of 5.3 Billion Lira
Net profit was 5.3 billion lira, compared with 11.6 billion lira a year earlier.
M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC
Google invertirá USD 15.000 millones en Malasia
La inversión prevista contempla centros de datos, energía y agua.
M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC
General Motors shares hit record high, up 4%
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC